Effect of toremifene in breast cancer patients. Preliminary communication

I. Hindy, É Juhos, J. Szántó, I. Számel

Research output: Contribution to journalArticle

8 Citations (Scopus)


Toremifene, an antiestrogenic drug administered at three dose levels (60, 120, and 300 mg/day) was investigated in 17 postmenopausal patients with advanced breast cancer previously treated with hormonal and/or cytostatic therapy. The drug proved to be well tolerated at all dose levels without any serious side effects even on prolonged administration. Neither response nor side effects have shown any dose dependency in this small group of patients.

Original languageEnglish
Pages (from-to)225-226
Number of pages2
JournalJournal of Steroid Biochemistry
Issue number3
Publication statusPublished - Jun 22 1990


ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this